Evaluation of Association between Flu-Like Syndrome Induced by Beta Interferon Drug and Required Drug Response in Patients with Multiple Sclerosis
Novelty in Biomedicine,
Vol. 7 No. 4 (2019),
9 August 2019
AbstractBackground: Beta interferon is one of the important drugs for multiple sclerosis. Its common side effects are flu-like symptoms caused by drug injection. The purpose of this study was to evaluate the possibility of predicting the response rate of this drug based on the flu-like drug reaction.
Materials and Methods: This case-control study performed in Loghman Hakim hospital in Tehran in 2017 and 110 patients with multiple sclerosis under beta interferon treatment studied. Patients were divided into two groups with and without flu-like drug reaction. A neurology resident according to the patient’s history and patient records filled in the questionnaires. The results of the two groups were compared by SPSS 16 software.
Results: A total of 110 patients including 31 patients with flu-like drug reaction and 79 non-complicated patients were evaluated. These patients included 32 males and 78 females with an average age of 35.55 years. The mean duration of beta interferon use was 4.33 years in the case group and 4.34 years in the control group. Finally, a significant correlation between the flu-like drug reaction and the optimal response in the first year treatment was found (p=0.026). In addition, cause of drug discontinuation had significant correlation with presence of flu like drug reaction (p=0.028). There was no significant correlation between the disease annual attacks rate and flu like drug reaction.
Conclusion: Flu-like drug reaction is a common complication of interferon beta drugs, which has a therapeutic difference in patients with and without this drug reaction.
- multiple sclerosis .beta interferon .Flu like drug side effect
Louis ED, Mayer SA, Rowland LP. Merritt's neurology (Thirteenth edition.). Philadelphia: Wolters Kluwer; 2016.
Ropper AH, Adams RD, Victor M, Brown RH, Victor M. Adams and Victor's principles of neurology. New York, McGraw-Hill Medical Pub. Division; 2014.
Eskandarieh S, Sahraian M, Moghadasi A, Azimi A. Multiple sclerosis prevalence and incidence in Tehran, Iran. ECTRIMS. 2016;e146156.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:655-61.
Lawrence D, Diane L, Cookfair T, Richard A, Rudick M, Herndon R, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol. 1998;39:285-94.
Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effects profile of interferon beta-1b in multiple sclerosis: results of a open label trial. Neurology.1996;46:552–4.
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996;39(3):285-94.
Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2006;113(5):283-7.
Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian MA, Henry D, et al. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments Published online 2013 Jun 22. doi: 10.1186/2008-2231-21-50
McDonagh M, Dana T, Chan BKS, Thakurta S, Gibler A. Drug class review on disease-modifying drugs for multiple sclerosis. Portland, OR: Oregon Health & Science University; July 2007.
Hartung HP, Bar-Or A, Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS? J. Neurol. 2004;5:12–29.
Hartung DM, Bourdette DN, Ahmed SM, Whitham RH. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail? Neurology. 2015;84:1–8.
Galloa P, Wijmeersc V. Overview of the management of relapsing"remitting multiple sclerosis and practical recommendations European Journax of Neurology. 2015:22;14–21.
Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consesus conference. Neurology 1996;46:12–18.
Mohr DC, Likosky W, Boudewyn AC, Marietta P. Side effect profile and adherence to in the treatment of Multiple Sderosis with interferon beta-la. Multiple Sclerosis. 1998;4:487-9.
. Gottberg K, Gardulf A, Fredrikson S. Interferon-beta treatment for patients with multiple sclerosis: the patients' perceptions of the side-effects. Mult Scler. 2000;6(5):349-54.
Nakatsuji Y, Nakano M, Moriya M, Kishigami H. Beneficial effect of interferon-b treatment in patients with multiple sclerosis is associated with transient increase in serum IL-6 level in response to interferon-b injection Cytokine. 36(2006):69–74.
Wiesemann E, Deb M, Hemmer B. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis Clinical Immunology. 2008;128:306–13.
Montalban X, Durán I, Río J, Torres I. Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-â? J Neurol. 2000;247:259–62.
Bertoli D, Serana F, Sottini A, Cordioli C. Less frequent and less severe flu like syndrome in interferon beta 1-a treated MS patients with at least one allele bearing the G>C polymorphism at position - 174 of the IL-6 promoter gene. PLOS. 2015(10);8:e0135441.
- Abstract Viewed: 92 times
- PDF Downloaded: 75 times